Market capitalization | $3.27b |
Enterprise Value | $2.66b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.95 |
P/S ratio (TTM) P/S ratio | 3.63 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 12.84% |
Revenue (TTM) Revenue | $900.66m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
16 Analysts have issued a PTC Therapeutics, Inc. forecast:
16 Analysts have issued a PTC Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 901 901 |
13%
13%
|
|
Gross Profit | 696 696 |
22%
22%
|
|
EBITDA | 22 22 |
107%
107%
|
EBIT (Operating Income) EBIT | -128 -128 |
75%
75%
|
Net Profit | -453 -453 |
29%
29%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
Head office | United States |
CEO | Matthew Klein |
Employees | 995 |
Founded | 1998 |
Website | www.ptcbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.